(See SNDX stock forecast on TipRanks) Biohaven Ltd. (BHVN) We’ll stay in the biotech space for the next JPM-endorsed name. Believing the other assets might also be “long-term drivers of share price performance,” Romero initiated coverage of BHVN with an Overweight (i.e., Buy) rating along with a $23 price target. Inflation remains high, the Fed has signaled that it will keep interest rates higher, longer, in response, and negative economic indicators keep piling up, pointing toward an increased likelihood of recession.